SCHEMBL1132891

SCHEMBL1132891

CCN(C[C@@H](N)COC)[C@@H](C)c1ccccc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.38
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
ACHE P22303 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 1/20 0.35
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
CA12 O43570 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
KDM4E B2RXH2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132507 0.86 MC4R (0.38) MC4RCA1CA2ACHEL3MBTL1
SCHEMBL1132362 0.86 MC4R (0.38) MC4RCA1CA2ACHEL3MBTL1
SCHEMBL1132873 0.86 MC4R (0.38) MC4RCA1CA2ACHEL3MBTL1
SCHEMBL1132743 0.85 MC4R (0.41) MC4RCA1CA2ACHEALDH1A1
SCHEMBL1132742 0.85 MC4R (0.41) MC4RCA1CA2ACHEALDH1A1
SCHEMBL1133072 0.85 MC4R (0.41) MC4RCA1CA2ACHEALDH1A1
SCHEMBL1132556 0.84 MC4R (0.36) MC4RCA1CA2ACHEL3MBTL1
SCHEMBL1132560 0.84 MC4R (0.36) MC4RCA1CA2ACHEL3MBTL1
SCHEMBL1132772 0.83 MC4R (0.39) MC4RCA1CA2ACHEL3MBTL1
SCHEMBL10245022 0.82 CA1 (0.44) MC4RCA1CA2ACHEL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 MC4R 489/4885CA1 4365/4885CA2 4058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.